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p53 and Rbl protein expression: are they prognostically
useful in colorectal cancer?
DN Poller, KJ Baxter and NA Shepherd
Department of Histopathology and Gloucester Gastroenterology Group, Gloucestershire Royal Hospital, Great Western Road, Gloucester GL1 3NN, UK
Summary The expression ofthe p53 and Rbl proteins was examined in an unselected consecutive series of 250 primary operable colorectal
carcinomas with a mean follow-up of 4.3 years (range 43-77 months). The overall cancer-specific mortality was 34.8%, with 87 cancer deaths
and 35 deaths as the result of other causes. Expression of p53 protein was identified in 152 of 250 (60.8%) cases, with expression of Rbl
protein in 207 of 250 (82.8%) cases. There was no association of p53 or Rb protein expression with patient age, sex, tumoursite, tumoursize,
tumour type, tumour grade, peritumoral fibrosis, tumour lymphocytic infiltrate, nature of the tumour margin, extramural vascular invasion,
number of lymph nodes or high apical lymph node involved or local peritoneal infiltration by tumour, Dukes' stage or Jass group. There was
no difference in overall survival or recurrence-free survival for those cases that showed p53 expression or Rbl protein expression compared
with those cases showing absence of p53 or Rbl protein expression, although patients with tumours showing aberrant (reduced) Rbl protein
expression demonstrated shorter recurrence-free survival and overall survival. The effect of 'aberrant' Rbl protein expression and shorter
recurrence-free and overall survival did not, however, achieve independent statistical significance. The results from this study would suggest
that expression of p53 and Rbl proteins does not appear be useful in determining the prognosis of operable colorectal cancer.
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The p53 and Rb] genes code for cell cycle-associated proteins
thought to be important in regulation ofthe normal cell cycle: p53
in the regulation ofthe G, checkpoint (Smith et al, 1994) and Rb]
by interaction with G, cyclins in the regulation of the GI phase
(Sherr, 1994). Mutant forms ofp53 no longer possess the ability
to arrest cell growth and induce apoptosis (Michalovitz et al,
1990) and are unable to bind specific DNA response sequences
and to activate the transcription of genes with an adjacent p53
recognition sequence (Kern et al, 1992). Much interest was
aroused by initial studies that showed that expression of p53
protein correlated with p53 gene mutations (Iggo et al, 1990),
although subsequent studies have shown that immunohistochem-
ical expression ofp53 may also occur in the absence ofp53 gene
mutations (Dunn et al, 1993; Kocialkowski et al, 1995; McManus
et al, 1994; Nylander et al, 1995). p53 mutations are thought to be
a late event in the adenoma-carcinoma sequence in colorectal
cancer (Fearon and Vogelstein, 1990). The sensitivity of the
method employed for p53 protein detection may have an impor-
tant role in the sensitivity ofdetection ofp53 using immunohisto-
chemistry (McKee et al, 1993). Abnormal (reduced or absent)
expression of Rbl protein is thought to occur in the presence of
deletions or mutations of the Rbl locus (Lemoine, 1994). The
object ofthis study was to examine the effect on patient prognosis
of tumour p53 and Rbl expression in a large prospective unse-
lected series ofcolorectal cancer.
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PATIENTS AND METHODS
Patients
The Gloucester Colorectal Carcinoma Study was established in
1988 by one author to examine the prognostic influence ofclinico-
pathological factors after surgery for colonic and rectal cancer
(Shepherd et al, 1995). All patients with primary operable
colorectal cancer treated at the Gloucestershire Royal Hospital
are entered into this study. Each patient is regularly followed up
at 6-monthly intervals with surgical outpatient assessment for
a minimum of 5 years with close co-operation of general prac-
tioners. Both 'curative' and 'palliative' cases are included,
although cases in which resection has been performed for meta-
chronous carcinoma, carcinoma arising in familial adenomatous
polyposis and ulcerative colitis are excluded. Cases are deemed
'curative' ifthe surgeon and/or pathologist believed that all tumour
had been removed at the end ofthe surgical procedure. No patients
were treated with adjuvant chemotherapy. All clinical, patholog-
ical, follow-up and survival data are entered on a computer data-
base and regularly updated by one research officer (KJB). Survival
time was calculated from the date of surgery to the date ofdeath or
last follow-up, with times censored for patients dying of causes
unrelated to colorectal cancer and those surviving. Cause of death
was established by autopsy or, in the absence of a post-mortem
examination, by careful assessment ofthe clinical case records.
Pathology
All resection specimens had been meticulously examined by NAS
as previously described (Shepherd et al, 1995) to assess tumour
site within the colon orrectum, tumour size, tumour type (standard
adenocarcinoma, mucinous or other), tumour grade (histological
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Table 1 p53 and Rbl expression and clinicopathological tumour variables
p53 Rbl Rbl
+ve -ve +ve -ve N Ab
Age (years)
<40
40-59
60-79
80-100
Sex
Male
Female
Site
Caecum
Ascending colon
Transverse colon
Descending colon
Sigmoid colon
Rectum
Tumour size (cm)
<2.5
2.5-4.9
5.0-7.4
7.5-9.9
10.0-12.4
12.5-15.0
Tumour type
Adenocarcinoma NOS
Mucinous
Other
Tumour grade
Well differentiated
Mod differentiated
Poorly differentiated
Lymphocytes
Prominent
Not prominent
Tumour margin
Pushing
Infiltrating
Vascular invasion
None
Present
Dukes' stage
A
B
C1
C2
1 0
23 12
97 68
31 18
X2=1.40
P=0.704
74 49
78 49
X2=0.041
P=0.839
21 13
20 14
18 15
4 3
40 21
49 32
X2=1.24
P=0.941
65 37
67 42
14 10
5 8
1 0
0 1
X2=5.36
P=0.373
141 82
9 16
2 0
X2=8.29
P=0.016
24 16
89 52
39 30
X2=0.860
P=0.651
22 9
130 89
X2=1.53
P=0.215
78 55
74 43
X2=0.553
P=0.457
87 56
65 42
X2=0.00021
P=0.988
18 11
49 39
73 42
12 6
X2=1.59
P=0.661
1 0
35 0
151 14
44 5
X2=3.62
P=0.306
110 13
121 6
X2=0.081
P=0.0813
33 1
29 5
32 1
7 0
56 5
74 7
X2=5.21
P=0.39
94 8
101 8
23 1
12 1
1 0
0 1
X2=12.7
P=0.027
206 17
23 2
2 0
X2=0.1 70
P=0.918
37 3
129 12
65 4
X2=0.486
P=0.784
14 5
205 26
X2=3.67
P=0.056
120 13
111 6
X2=1.91
P=0.166
130 13
101 6
X2=1.057
P=0.304
25 4
81 7
108 7
17 1
X2=2.08
P=0.556
1 0
18 17
54 111
14 35
X2=7.29
P=0.063
40 83
47 80
X2=0.554
P=0.456
10 24
11 23
13 20
3 4
26 35
24 57
X2=3.63
P=0.604
37 65
36 73
8 16
5 8
1 0
0 1
X2=2.75
P=0.738
80 143
6 19
1 1
X2=1.60
P=0.448
16 24
46 95
25 44
X2=0.833
P=0.659
10 21
77 142
X2=0.-Ol
P=0.751
48 85
39 78
X2=0.208
P=0.648
47 96
40 67
X2=0.550
P=0.458
10 19
31 57
44 71
2 16
X2=5.06
P=0.167
differentiation), degree of intratumoral fibrosis, presence or
absence of a prominent tumour lymphocytic infiltrate, nature of
the invasive tumour margin (pushing or infiltrating) and presence
of extramural vascular or lymphatic invasion. The number of
lymph nodes containing metastatic carcinoma, high lymph node
involvement adjacent to the apical vascular tie (indicating Dukes'
C2 stage), local peritoneal infiltration by tumour, Dukes' stage
(A, B, Cl or C2), Jass grade and Australian Clinicopathological
Staging systems were also assessed (Shepherd et al, 1995). For the
purposes of the current study, representative archival tumour
blocks were selected for 250 consecutive patients early in the
study to maximize the length offollow-up.
Immunohistochemistry
Representative blocks of formalin-fixed paraffin-embedded
tumour tissue were cut at 4-jum thickness, dewaxed in xylene and
then rinsed in alcohol and graded alcohol/water mixtures. A stan-
dard avidin/biotin peroxidase technique was used. Incubation with
the primary p53 antibody DO-1 (Vojtesek et al, 1992) (Professor
DP Lane, Cancer Research Campaign Molecular Oncogenesis
Unit, University Of Dundee) was performed for 30 min at a dilu-
tion of 1:100. DO-1 is a well-characterized monoclonal antibody
that recognizes an epitope near the N-terminus of both wild and
mutant p53 proteins (Vojtesek et al, 1992). Following incubation
with the primary antibody, a secondary polyclonal biotinylated
swine anti-rabbit antibody was used (Dako UK, High Wycombe,
Bucks, UK). This was followed by an avidin-biotinylated peroxi-
dase complex, with 3,3-diaminobenzidene as the chromogen. For
the detection of Rbl protein, the monoclonal antibody 14,0001A
was used (PharMingen, San Diego, CA, USA) at a dilution of
1:100, followed by a secondary polyclonal biotinylated swine anti-
rabbit antibody (Dako UK) with an avidin-biotinylated peroxidase
complex, with 3,3-diaminobenzidene as the chromogen.
Scoring and interpretation of results
All sections were incubated in batches of 30-40 tumours with a
tumour of known positive immunoreactivity with each run of
immunostaining. Only nuclear staining oftumournuclei was inter-
preted to indicate positive tumour p53 or Rbl immunoreactivity.
All tumour sections were examined by DNP. The percentage of
tumour nuclei staining across the whole tumour section was
recorded subjectively in five categories as follows: 0%, 1-24%,
25-49%, 50-74%, 75-100%; and the grading of the intensity of
immunostaining was recorded in fourcategories (0, 1, 2, 3), with 0
indicating no nuclear staining, 1 very weak nuclear staining, 2
intermediate nuclear staining and 3 strong nuclear staining. The
score for intensity was always that of the most strongly stained
Table 2 Local recurrence p53 and Rbl staining
p53 Rbl
+ve -ve +ve -ve
No evidence of recurrence 126 81 192 15
Local recurrence 26 17 39 4
X2=0.0024 X2=0.643
P=0.960 P=0.214
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Rbl +ve or-ve indicates overall positive or negative Rbl staining. N, normal
staining; Ab, aberrant staining.
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nucleus in any section, not the median intensity of nuclear
staining. In occasional cases of doubt as to the interpretation of
staining results, ajoint decision was made with NAS after exami-
nation of tumour sections using a conference microscope. For the
purposes ofstatistical analysis, p53 expression was treated as posi-
tive ifany tumour showed nuclear staining forp53; and for Rbl, a
positive result was noted ifany tumour nucleus showed expression
of Rbl protein. Aberrant Rbl expression, for the purposes of this
study, was defined as any tumour showing less than 50% of
tumour nuclei with Rbl protein expression.
Statistical analysis
Data were analysed using Statistica, a computer software package
for a Windows IBM-compatible personal computer. The recur-
rence-free survival and overall survival analyses were performed
using the log-rank test (Mantel, 1966). Multivariate analyses were
performed using the Cox proportional hazards model (Cox, 1972).
RESULTS
p53 immunostaining
The results of p53 immunostaining and clinical variables are
shown in Tables 1 and 2 and Figure 1. There was little or no
evidence ofcytoplasmic staining forp53 withDO-1. No staining of
normal crypt epithelial cells was identified, although very weak
staining ofbasal crypt epithelial cells was visible in some cases in
transitional mucosa adjacent to tumours. One hundred and fifty-
two of 250 (60.8%) cases showed positive tumour p53 staining
(Table 1). The pattern of staining was variable between tumours,
some showing strong generalized nuclear immunoreactivity for
p53 throughout the tumour sections, whereas others did not. Some
showed larger nuclei with strong focal p53 staining. There was no
relationship between tumour p53 expression and patient age, sex,
site of tumour, tumour size, tumour type (standard adenocarci-
noma or mucinous), tumour grade, peritumoral lymphocytic infil-
trate, nature ofthe invasive tumour margin, extramural vascular or
lymphatic invasion, lymph node involvement, high tie lymph node
involvement, involvement of the peritoneum by tumour and
Dukes' stage. There was no relationship oftumourp53 expression
with recurrence-free survival oroverall patient survival (Figure 2).
There was a direct relationship between p53 and Rbl staining
(Table 2).
Rb 1 immunostaining
Positive nuclear Rbl staining was seen in the majority of tumours
examined - 207 of 250 (82.8%) cases (Table 1 and Figure 3). No
cytoplasmic staining was seen for Rbl. Positive Rbl staining was
also seen in the nuclei ofcrypt cells oftransitional mucosa adjacent
to the invasive tumours. There was again no relationship between
tumour Rbl protein expression and patient age, sex, site oftumour,
tumour size, tumour type (standard adenocarcinoma or mucinous),
tumour grade, peritumoral lymphocytic infiltrate, nature ofthe inva-
sive tumour margin, extramural vascular or lymphatic invasion,
lymph node involvement, involvement ofthe peritoneum by tumour
and Dukes' stage. There was no relationship between tumour Rbl
expression and recurrence-free survival or overall patient survival
(Figures 4 and 5). Reduced or 'aberrant' Rbl staining was also
examined. This showedthatthegroup oftumours withlessthan 50%
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Figure 1 Tumour nuclei staining strongly (intensity score=3) with antibody
DO-1 (x 190 magnification)
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Figure 2 p53 status and overall survival. Z=-0.926, P=0.177 (NS)
Rbl staining appeared in univariate analysis to have reduced overall
and recurrence-free survival. However, in multivariate Cox propor-
tional hazards analysis, the prognostic effect ofaberrant Rbl protein
expression failed to achieveindependent prognostic significance.
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Table 3 p53 and Rbl expression
Rbl p53
+ve -ve
Rbl-ve 6 13
Rbl+ve 146 85
x2=7.37
P=<0.01
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Figure 4 Tumour Rbl status and overall survival (any tumour nucleus +ve
compared with tumours showing all nuclei with -ve staining). Z=0.0148,
P=0.494 (NS)
0.9-
0)
a
, 0.8-
, 0.7- CD
.2 0.6-
0 0. 0.5- 0
g 0.4-
1 0.3-
E 0.2-
0
0.1 -
-p.._|
a-- unaltered rbl (n=87)
* altered rbl (n=163)
Time (months)
Number entering
Interval
0 I
0 8.5 17 25.5 34 42.5 51 59.5 68 76.5
87 75 67 60 57 54 36 26 9
163 129 109 102 92 86 56 30 13
Figure 5 Tumour Rbl status and aberrant Rbl expression. Z- 1.82,
P=0.034 (Significant)
Figure 3 Tumour nuclei staining focally and strongly (intensity score=3) with
antibody 14,001A (x235 magnification)
DISCUSSION
This is one of the largest studies to assess the prognostic implica-
tion of p53 expression in colorectal cancer. The results show that
there was little or no prognostic effect of p53 and Rbl protein
expression in a large unselected series of colorectal carcinomas.
This finding accords with some recent reports in the literature but
not with other previously published series. A novel relationship
betweenp53 and Rbl protein expression has been identified in this
study. It was initially suggested thatdetection ofp53 protein corre-
lated with p53 gene mutations (Iggo et al, 1990). However, there
are a large number ofpathological studies in which immunohisto-
chemical p53 protein analysis has been examined together with
p53 gene mutations in a variety oftumourtypes (Dunn etal, 1993;
Baas et al, 1994, 1996; McManus et al, 1994; Kocialkowski et al,
1995; Nylander et al, 1995). It has been stated that mutation ofthe
p53 gene is one of the commonest mutations in human cancers,
although mutations ofp53 occur late in the adenoma-carcinoma
sequence ofcolorectal cancer (Fearon and Vogelstein, 1990). p53
mutations may, however, occur early in some pathways and later
in other tumour types. Expression ofp53 may occur in aconsider-
able number of cases in which p53 gene mutations are not
detectable by polymerase chain reaction (PCR) (Baas et al, 1994,
1996). This again is not surprising; p53 is a normal constitutive
cell cycle-associated protein, and the ability to detect p53 protein
in archival formalin-fixed paraffin-embedded tissue is dependent
on the sensitivity of the antigen retrieval system employed. The
microwave antigen retrieval system used for detection of p53
and Rbl in the present study is quite likely to have improved the
sensitivity ofp53 and Rbl antigen detection (McKee et al, 1993,
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Table 4 p53 and prognosis in colorectal carcinoma
Reference Number p53 poor Multivariate analysis Yes/No
of cases prognostic and other comments
in series factor
Scott et al (1991)
Remvikos et al (1992)
Starzynska et al (1992)
Sun et al (1992)
Yamaguchi et al (1992)
Bell et al (1993)
Sun et al (1993)
Yamaguchi et al (1993)
Auvinen et al (1994)
Goh et al (1994)
Hamelin et al (1994)
Nathanson et al (1994)
Zeng et al (1994)
Bertorelle et al (1995)
Mulder et al (1995)
Ofner et al (1995)
52
78
107
N
y
y
293
100
100
293
203
144
187
85
y
y
N
y
y
y
y
y
84 N
107
83
109
109
y
y
N
N
No MVA. Small series, no effect of
p53 on survival
No MVA. No effect of p53 on
survival when Dukes''D' cases
excluded
No MVA. One year clinical follow-up,
adverse survival in group of p53 +ve
cases
MVA - yes. Cytoplasmic notnuclear
p53 expression associated with adverse
survival
MVA - yes. Three-year survival significantly
worse forp53-expressing cases
No MVA. No effect of p53 on survival
except in ten cases also showing Ki ras
mutations
MVA - yes. Nuclear and cytoplasmic
p53 expression associated with adverse
prognosis in Dukes' A, B and C
tumours
No MVA. p53-positive cases associated
with adverse 5-year survival
No MVA. Overall survival reduced in
p53+ve tumours
No MVA. PCR and immuno-
histochemical study showing that
lymphatic dissemination associated with
p53mutation
MVA - yes. PCR study showing adverse
effect of p53 mutations on survival
(median 47 months)
MVA - yes. No statistically significant
relationship of p53 and overall survival
identified
MVA - yes. Study conducted on Dukes'
C or above patients with low CEA
levels
No MVA. Increased frequency of liver
and nodal metastases in p53+ve
tumours. Overall survival was not
assessed
MVA - yes. p53 expression not an
independent marker of prognosis
No MVA. p53 expression not an
independent marker of prognosis
Baas et al, 1996), implying that a considerable proportion ofp53-
staining cases would show absence of p53 mutations. Equally,
cases 'aberrantly staining' for Rbl might also not harbour RbJ
gene mutations.
Other studies have examined the prognostic effect of pS3
protein expression in colorectal cancer (see Table 4), and most
would suggest that expression of p53 is an adverse prognostic
factor. The immunohistochemical evidence for a relationship
between p53 expression and adverse prognosis has been corrobo-
rated either by studies of total tumour p53 or by PCR analysis of
p53 gene mutations (see Table 4).
One conflicting study showed that a group of patients with
either nil or strong p53 protein expression fared worse than
patients showing intermediate staining for p53 (Nathanson et al,
1994). It has also been suggested thatp53 protein expression in the
cytoplasm rather than the nucleus itselfmay be a predictor ofpoor
prognosis in colorectal cancer, and that nuclear p53 staining is not
an adverse prognostic factor (Sun et al, 1992). Thirty of293 cases
of colorectal carcinoma showed pure cytoplasmic p53 expression.
This particular study was, however, performed with a polyclonal
antibody, CM 1, and the number of cases showing pure cyto-
plasmic staining was small. The same authors also showed that
both nuclear and p53 protein expression appeared to be important
in a multivariate analysis (Sun et al, 1993). A further study (Ofner
et al, 1995) showed that there was no relationship between p53
protein expression and grade or stage parameters, such as Dukes'
stage, in colorectal cancer. This finding has been reiterated
(Mulder et al, 1995) in a study of 109 colorectal cancers. p53
expression was found to be more frequent in non-mucinous
tumours and in metastatic tumours than in primary carcinomas.
British Journal ofCancer(1997) 75(1), 87-93 0 CancerResearch Campaign 199792 DN Poller etal
Dukes' stage and pathological grade were independent prognostic
variables, whereas p53 was not an independent prognostic marker.
To our knowledge, this is one ofthe largest studies to assess the
prognostic implications of p53 expression in colorectal cancer.
These results show that there is no prognostic effect of p53 and
Rb1 protein expression. This finding accords with some reported
results in the literature but not others. A relationship between p53
and Rbl protein expression was identified; this finding is novel.
There is little if any published literature on Rb1 and prognosis in
colorectal cancer. The expression of Rbl protein was examined in
50 cases of colorectal cancer showing localization of the Rb1
protein to the nucleus of tumour cells (Yamaoto et al, 1995).
Strong expression was seen in 17 cases, intermediate expression in
22 cases and weak (up to 10% of the nuclei staining) in 11 cases.
The lack of association of Rbl staining and other prognostic
factors in colorectal cancer is not particularly surprising. The RbI
protein is thought to play a role in the G, phase and mutations of
the Rbl protein are thought to be important in tumorigenesis of
second tumours, in particular sarcomas, in patients with retinoblas-
toma gene mutations. The idea that lack of expression of the Rbl
protein (which should, by inference, be associated with Rb] gene
'double knockout') would be an adverse prognostic factor in
colorectal cancer has not been examined. It is interesting to
contrast our findings in colorectal cancers with those in sarcomas.
Adverse prognosis has been associated with reduced or 'aberrant'
expression ofRb1 protein in tumours with heterogeneous or absent
expression ofthe Rb] gene product (Cance et al, 1990).
The results from this study imply that expression ofp53 and Rbl
proteins does not appear to be a useful prognostic factor in
colorectal cancer while coexpression of p53 and Rbl proteins is
present in colorectal cancer. The apparent discrepancy ofpublished
results in the literature may to some extent reflect publication
biases particularly as many studies show an effect ofp53 on overall
prognosis but not on other important prognostic parameters, such
as tumour stage, or in subsets of particular patients in any given
study but not in whole cohorts ofpatients.
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